Psoriatic Arthritis Panel: EULAR 2025
Panelists Drs. Aurelie Najm, Eric Ruderman, Nelly Ziade, Jiha Lee and Jack Cush review highlights of PsA abstracts and sessions presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →What's hot!
View all perspectives
What's Hot
Spondyloarthritis Panel: Eular 2025
Panelists: Drs. Peter Nash, Yuz Yusof, Antoni Chan, Adela Castro and Jack Cush.
Watch video →
Steroids, Not JAKi, Are the Real Infection Risk
Dr. David Liew reporting at EULAR 2025 in Barcelona, Spain.
Watch video →
Seronegative Arthritis Breakthroughs
Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors" and POS0016, "Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Psoriatic Arthritis", presented at EULAR 2025 in Barcelona, Spain.
Watch video →
JAK Safety Update
Dr. Jonathan Kay offers his perspectives on abstracts POS0150, POS0151, and POS0157 presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
Who/When to Treat Clinically Suspect Arthralgia
Dr. Jack Cush discusses risk stratification in Clinically suspect arthralgia; referencing EULAR2025 abstracts OP0004 (ALTO study) and OP0325 (long term Followup of ARRIA)
Watch video →
Hidradenitis Suppurativa: What Lies Beneath?
Dr. David Liew reports on abstract POS1237 presented at the EULAR 2025 meeting in Barcelona, Spain.
Watch video →
The Value of Kidney Biopsy in Autoimmune Diseases
Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting in Barcelona, Spain.
Watch video →
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data, represents a significant step in refining our understanding and management of the most treatment-resistant forms of RA.
Read more →
Frequent dosing in PsA: Less or More?
Dr. Eric Ruderman offers his perspective after reviewing abstract POS0016 about less or more frequent dosing in psoriatic arthritis at the 2025 EULAR meeting in Barcelona
Watch video →
Rheumatology RoundUp: EULAR 2025
Featuring Drs. Arthur Kavanaugh and Jack Cush. Abstracts discussed:OP0107OP0325OP0105LB0010POS1051POS1160POS0017POS0173LB0005
Watch video →
New IL-17 Inhibition New Molecular Constructs
Dr. Philip Mease offers his perspective from the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
Rituximab - Super Responders Exist in SLE
Dr. Yuz Yusof reports on abstract POS0325 presented at the 2025 EULAR meeting in Barcelona.
Watch video →
IL-17 Inhibitors for Axial Spondyloarthritis
Dr. Philip Mease discusses take-home messages from the IL-17 in axSpA data presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
IL-17 Inhibitors in Psoriatic Arthritis
Dr. Philip Mease offers his perspective on IL-17 inhibitors in psoriatic arthritis presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
What we need in very early arthritis
It's easy to think that in our current world that we've done it all for rheumatoid arthritis, that there's nothing left to be done after b/tsDMARDs have become relatively widespread and accessible. If we aren’t satisfied that we’ve done all we can for our RA patients, how can we make their treatment and their lives better?
Read more →
Trends and Innovations from Barcelona (6.20.2025)
Dr. Jack Cush reviews highlights, trends and novel studies from EULAR 2025 in Barcelona from last week.
Read more →
All Rheumatoid Arthritis is Not the Same
Dr. Jonathan Kay reviews abstracts OP0323 and OP0328 from the EULAR 2025 meeting in Barcelona, Spain.
Watch video →
Nelly ZIADE 🍀 Nellziade
11 months ago
FAPI-PET/CT - detecting synovial and enthesial fibroblast activation- predicts the development of #psoriatic_arthritis in patients with psoriasis and arthralgia
✨️ A promising tool for early diagnosis of PsA
Giulia Corte et al.
OP#0174
#EULAR2025
@RheumNow https://t.co/QVmoECIhBI
Aurelie Najm AurelieRheumo
11 months ago
Ph 2 RCT CPL'116 dual inhibition JAK/ROCK
106 MTX IR pts
wk12 primary endpoint met (DAS28-CRP decrease) in 240mg arm vs. PBO
75% >= AEs, SAE 2: 1 MI, 1 bladder cancer
Authors suggest absence of lipids/LFTs disruption compared to other JAKs
Ph3 is awaited!!
#OP0193 #EULAR2025 https://t.co/TnnM410LfM
Nelly ZIADE 🍀 Nellziade
11 months ago
✨️ New Definition Alert
The GRAPPA definition of
C2M (Complex to Manage)
&
D2T (Difficult to Treat)
#Psoriatic_arthritis
A hope for having a homogeneous and widely accepted definition for future clinical research
Presented at #EULAR2025
Proft et al.
OP#0175
@RheumNow https://t.co/et9cuMROkb
Aurelie Najm AurelieRheumo
11 months ago
Combination of LEF and MTX in RA: Yay or Nay?
#EULAR2025 @RheumNow
Jiha Lee JihaRheum
11 months ago
OP0195: MTX+LEF isn’t commonly used—but could it be a viable option after all?
In >1,100 RA pts, no link to liver fibrosis (FIB-4/APRI), modest ALT ↑, and fewer hospitalizations.
real-world safety data worth a second look.
@RheumNow #EULAR2025
Jiha Lee JihaRheum
11 months ago
OP0179: In a psoriasis cohort, 68% of PsA onset sites showed prior subclinical inflammation (26% tender, 32% US+, 42% both).
Should we redefine when PsA truly begins?
@RheumNow #EULAR2025
Mrinalini Dey DrMiniDey
11 months ago
ACQUIVAS: RTX-treated AAV patients had poor response to #pneumococcal vaccine PCV-13 (8% vs 45% in non-RTX). Boosting w/ PPV-23 helped a few but 48% failed to mount robust response. Time to rethink vaccine strategies in RTX-treated patients?
@RheumNow #EULAR2025 #OP0173 https://t.co/soU5qfwRib
Aurelie Najm AurelieRheumo
11 months ago
Premature death in RA still exists, and varies according to race/ethnicity demographic groups
Nationwide US CDC's MCoD database analysis
-Mortality rates
11x higher American Indians
3x higher Black or African American people
-Median age at death with RA
9-10 years younger https://t.co/FTRWPk7Wz0
Mrinalini Dey DrMiniDey
11 months ago
#MITIGATE subgroup analysis: Inebilizumab reduced flares & boosted remission across all #IgG4-RD subgroups. HR for flare vs PBO: 0.12-0.16 across sex/race. Similar results for all subgroups in achieving flare-free, treatment-free complete remission.
@RheumNow #EULAR2025 #OP0189
Mrinalini Dey DrMiniDey
11 months ago
RA-related premature mortality highest in American Indians--> 3.6x odds of death in <65 vs White peers, w/ no improvement over 22 yrs. COVID widened the gap. Need to address structural & social drivers of early death in RA, & wider health disparities.
@RheumNow #EULAR2025 #OP0197
Aurelie Najm AurelieRheumo
11 months ago
Yes, it is relevant to ask patients about physical joint strain in RA and propose strain specific interventions
In ACPA+ RA pts for each 10% increase in strain, 7% increase in SJC44 and 5% MRI inflammation
POS0166 #EULAR2025 @RheumNow https://t.co/jwpi7S8JTW
Aurelie Najm AurelieRheumo
11 months ago
We should address patients anxiety at RA diagnosis:
cohort 250+ newly diagnosed RA pts
-49% reported anxiety
-41% by 3 months
Anxiety asso w/ CDAI, PROs and 3-5 fold increase in prescription of bio/tsDMARDs
Analysis reasonably adjusted
POS0163 #EULAR2025 @RheumNow https://t.co/2gejEkRQhO
Aurelie Najm AurelieRheumo
11 months ago
BioDMARDs reduce polyimmunity in RA
Danish Registry based cohort study 5 yrs follow up
25000+ pts
Polyimmunity in csDMARDs treated group 2.2% vs. 1.7% in bioDMARDs group
HR 0.74
Most frequent autoimmune thyroid disease
POS0161 #EULAR2025 @RheumNow https://t.co/9T0mhoUuqs
Antoni Chan MD (Prof) synovialjoints
11 months ago
In D2T-PsA (10%), 57% had persistent inflammation (PIPsA), 43% non-inflammatory (NIPsA). Ultrasound distinguished phenotypes: median US activity score 3.22 vs 0.88.,swollen joints 2.5 vs 0, tender points higher in NIPsA.
Abstract OP0176 @RheumNow #EULAR2025 https://t.co/k7m8gAzbAZ
Antoni Chan MD (Prof) synovialjoints
11 months ago
Nordic registries (n=13,872): D2T-PsA varied 37% (≥2 b/tsDMARDs failed) to 0.6% (strictest). Female predominance increased with therapy failures (≥4 failures: 67% female). Median time to failure: 5–7 years.
Abstract OP0177 @RheumNow #EULAR2025 https://t.co/lchPnTCEx7
Poster Hall